Seizures in Primary Antiphospholipid Syndrome: The Relevance of Smoking to Stroke
Carregando...
Citações na Scopus
29
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
HINDAWI PUBLISHING CORPORATION
Autores
Citação
CLINICAL & DEVELOPMENTAL IMMUNOLOGY, article ID 981519, 7p, 2012
Resumo
Objectives. To evaluate the frequency of seizures in primary antiphospholipid syndrome (PAPS) and their possible clinical and laboratory associations. Methods. Eighty-eight PAPS patients (Sydney's criteria) were analyzed by a standard interview, physical examination and review of medical charts. Risk factors for seizures, clinical manifestations, associated comorbidities, and antiphospholipid antibodies were evaluated. Results. Nine (10.2%) patients with seizures were identified, 77.8% had convulsions onset after PAPS diagnosis. Mean age, gender, and race were comparable in groups with or without seizures. Interestingly, a higher frequency of current smoking (44.4 versus 10.1%, P = 0.019) was observed in the first group. Stroke, Sneddon's syndrome, and livedo reticularis were more frequent in PAPS patients with seizures than those without seizures, although not statistically significant (P > 0.05). Comparison between patients with seizures onset after PAPS diagnosis (n = 7) and those without convulsions (n = 79) demonstrated a higher frequency of current smoking (42.9 versus 10%, P = 0.042) and stroke in the first group (71.4 versus 30.4%, P = 0.041). Regression analysis confirmed that smoking (P = 0.030) and stroke (P = 0.042) were independently associated to seizures. Conclusion. About 10.2% of PAPS patients had convulsions, predominantly after PAPS diagnosis, and seizures were associated to current smoking and stroke.
Palavras-chave
Referências
- Appenzeller S, 2004, NEUROLOGY, V63, P1808
- Arbuckle MR, 2003, NEW ENGL J MED, V349, P1526, DOI 10.1056/NEJMoa021933
- ASHERSON RA, 1989, AM J MED, V86, P391, DOI 10.1016/0002-9343(89)90335-5
- Bensenor IM, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-298
- Blume Warren T., 2001, Epilepsia, V42, P1212, DOI 10.1046/j.1528-1157.2001.22001.x
- Broide RS, 2002, MOL PHARMACOL, V61, P695, DOI 10.1124/mol.61.3.695
- Cervera R, 2002, ARTHRITIS RHEUM, V46, P1019, DOI 10.1002/art.10187
- Chapman J, 1999, LUPUS, V8, P127, DOI 10.1191/096120399678847524
- COCITO L, 1982, STROKE, V13, P189
- DEFIEBRE CM, 1988, ALCOHOL, V5, P55, DOI 10.1016/0741-8329(88)90044-4
- Dworetzky BA, 2010, EPILEPSIA, V51, P198, DOI 10.1111/j.1528-1167.2009.02268.x
- Erkan D, 2007, ARTHRITIS RHEUM, V56, P2382, DOI 10.1002/art.22663
- Erkan D, 2009, NAT CLIN PRACT RHEUM, V5, P160, DOI 10.1038/ncprheum1017
- ESPARZA RH, 1985, J RHEUMATOL, V12, P1109
- Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x
- Gualtierotti R., CLIN REV AL IN PRESS
- HUGHES GRV, 1983, BRIT MED J, V287, P1088
- LIOU HH, 1994, LIFE SCI, V54, P1119, DOI 10.1016/0024-3205(94)00422-6
- Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x
- MOORE PM, 1995, SPRINGER SEMIN IMMUN, V17, P43
- Pierangeli SS, 2008, NAT PROTOC, V3, P840, DOI 10.1038/nprot.2008.48
- Ribeiro AR, 2010, ACTA REUMATOL PORT, V35, P36
- Rodrigues CEM, 2010, EUR J CLIN INVEST, V40, P350, DOI 10.1111/j.1365-2362.2010.02263.x
- Ruiz-Irastorza G, 2010, LANCET, V376, P1498, DOI 10.1016/S0140-6736(10)60709-X
- Sanders R. W., 2009, J EMERGENCY MED
- Sanna G, 2003, RHEUMATOLOGY, V42, P200, DOI 10.1093/rheumatology/keg080
- Shoenfeld Y, 2004, J RHEUMATOL, V31, P1344
- Tan EM, 1980, MANUAL CLIN IMMUNOLO, P866
- Wisloff F, 2002, THROMB RES, V108, P263, DOI 10.1016/S0049-3848(02)00400-0
- [Anonymous], 2006, IDF CONS WORLDW DEF